-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune thrombocytopenia is a rare autoimmune disease, with the risk of bleeding and fatigue
.
The recommended first-line treatment for immune thrombocytopenia is high-dose glucocorticoids, but side effects, variable responses, and high recurrence rate are serious shortcomings of this treatment
immunity
Recently, a research article was published in the top medical journal NEJM.
In this multi-center, open-label, randomized, controlled trial conducted in the United Kingdom, researchers assigned adult patients with immune thrombocytopenia at a ratio of 1:1 Use only glucocorticoids (standard treatment) or a combination of glucocorticoids and mycophenolate mofetil
.
The main efficacy outcome of the study was treatment failure, which was defined as a platelet count lower than 30×109/L and second-line treatment was initiated
The study included a total of 120 patients with immune thrombocytopenia for randomization (52.
4% for men; average age 54 years [range 17 to 87]; average platelet level 7×109/L) and started Follow-up was up to 2 years after trial treatment
.
The treatment failure rate of the mycophenolate mofetil group was lower than that of the glucocorticoid-only group (22% [13 of 59 patients] vs.
The researchers found no evidence of differences in bleeding, rescue treatment, or treatment side effects (including infection ) between the groups
.
However, patients in the mycophenolate mofetil group reported worse quality of life results in terms of physical function and fatigue than patients in the glucocorticoid-only group
Infect
It can be seen that adding mycophenolate mofetil to glucocorticoids for first-line treatment of immune thrombocytopenia can achieve greater therapeutic response and reduce the risk of refractory or recurrent immune thrombocytopenia , But the quality of life has declined
.
.
Original source:
Charlotte A.
Bradbury, et al.
Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia .
